Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) filed a Next Day Disclosure Return with the Hong Kong Stock Exchange on 22 April 2026, detailing a fresh repurchase of its H shares.

On 22 April 2026, the company bought back 160,000 H shares on-market at prices between HK$3.59 and HK$3.61, for a volume-weighted average of HK$3.6013. The aggregate consideration amounted to HK$0.58 million. The repurchased shares—representing 0.0036 % of the company’s issued H shares (excluding treasury shares) prior to the transaction—were retained as treasury stock.

Following the operation: • Issued shares (excluding treasury shares) decreased from 4.470 billion to 4.46989 billion. • Treasury shares increased from 52.29 million to 52.45 million. • Total issued shares remained unchanged at 4.52233 billion.

The buyback formed part of the mandate approved on 27 May 2025, which authorises Weigao Group to repurchase up to 451.56 million shares. Cumulative repurchases under this mandate now stand at 45.80 million shares, equivalent to 10.14 % of the outstanding share base on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 23 May 2026.